Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4783397
Max Phase: Preclinical
Molecular Formula: C20H22N4O6S2
Molecular Weight: 478.55
Molecule Type: Unknown
Associated Items:
ID: ALA4783397
Max Phase: Preclinical
Molecular Formula: C20H22N4O6S2
Molecular Weight: 478.55
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Nc1nc2sc(CCCCc3cc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cs3)cc2c(=O)[nH]1
Standard InChI: InChI=1S/C20H22N4O6S2/c21-20-23-17(28)13-8-12(32-18(13)24-20)4-2-1-3-11-7-10(9-31-11)16(27)22-14(19(29)30)5-6-15(25)26/h7-9,14H,1-6H2,(H,22,27)(H,25,26)(H,29,30)(H3,21,23,24,28)/t14-/m0/s1
Standard InChI Key: UEVAKXKCGSGJIG-AWEZNQCLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 478.55 | Molecular Weight (Monoisotopic): 478.0981 | AlogP: 2.24 | #Rotatable Bonds: 11 |
Polar Surface Area: 175.47 | Molecular Species: ACID | HBA: 8 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 3.68 | CX Basic pKa: 3.37 | CX LogP: 1.94 | CX LogD: -3.53 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.26 | Np Likeness Score: -0.74 |
1. Wallace-Povirk A,Tong N,Wong-Roushar J,O'Connor C,Zhou X,Hou Z,Bao X,Garcia GE,Li J,Kim S,Dann CE,Matherly LH,Gangjee A. (2021) Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors., 37 [PMID:33773393] [10.1016/j.bmc.2021.116093] |
Source(1):